JC20 Rec'd PCT/PTO 2 6 SEP 2005

Sheet 1 of 1

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.	Serial No.	
(Nev. 2-32)		05-765	To Be Assigned 550667	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT		79000	
	Use several sheets if necessary)			
`	Ose several sileets if flecessary)		L	
		Applicant:		
		Starck et al.		
		Filing Date:	Group:	
		Herewith	To Be Assigned	

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	A1	4,624,963 A	November 25, 1986	Kruse et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initial							Trans	slation
		Document Number	Date	Country	Class	Subclass	Yes	No
	A2	WO 94/29272 A	December 22, 1994	PCT				X
	A3	WO 98/01428 A	January 15, 1998	PCT				Х
	A4	EP 0 445 781 A	September 11, 1991	EPO				X
	A.5	EP 0 022 317 A	January 14, 1981	EPO				X
	A6	JP 1 095766 A	April 13, 1989	Japan				Х

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

	A7	Chemical Patents Index, Documentation Abstracts Journal, Section Ch, Week 9627, Class B02, AN 96-266522. XP002241135		
	A8	Nilsson, I. et al., <i>Acta Chem. Scand. Ser. B</i> , 1985 , Vol. 39, No. 7, p. 531-548.		
	A9	Bell, M. et al., <i>J. Med. Chem.</i> , 1991 , Vol. 34, No. 3, pp. 1099-1110.		
	A10	Hotzel, C. et al., "Design, Synthesis, DNA-Binding and Cytotoxicity Evaluation of New Potential Combilexines", European Journal of Medicinal Chemistry, 2002, Vol. 37, No. 5, pp. 367-378.		
EXAMINER			DATE CONSIDERED	

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.